Cyberonics' delight at US move on VNS therapy for depression
This article was originally published in Clinica
Executive Summary
A pacemaker-like device that fires mild electrical impulses into the vagus nerve should be allowed onto the US market to treat chronic depression, an FDA advisory panel decided on June 15. The neurological devices panel voted 5-2 to recommend that the VNS Therapy System, manufactured by Houston, Texas-based Cyberonics, be approved subject to certain conditions, despite their concerns about the clinical data and the possibility that the results were merely a placebo effect.